Your browser doesn't support javascript.
loading
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Ravandi, Farhad; Cloos, Jacqueline; Buccisano, Francesco; Dillon, Richard; Döhner, Konstanze; Freeman, Sylvie D; Hourigan, Christopher S; Ossenkoppele, Gerrit J; Roboz, Gail J; Subklewe, Marion; Thiede, Christian; Arnhardt, Isabell; Valk, Peter J M; Venditti, Adriano; Wei, Andrew H; Walter, Roland B; Heuser, Michael.
Afiliación
  • Ravandi F; Department of Leukemia, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
  • Cloos J; Department of Hematology, Amsterdam University Medical Center (UMC), Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Buccisano F; Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy.
  • Dillon R; Department of Medical and Molecular Genetics, King's College, London, UK.
  • Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Hourigan CS; Laboratory of Myeloid Malignancy, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
  • Ossenkoppele GJ; Department of Hematology, Amsterdam University Medical Center (UMC), Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Roboz GJ; Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Subklewe M; Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, München, Germany.
  • Thiede C; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Arnhardt I; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Valk PJM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Venditti A; Department of Biomedicine and Prevention, Hematology, University Tor Vergata, Rome, Italy.
  • Wei AH; Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Walter RB; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Am J Hematol ; 98(12): 1847-1855, 2023 12.
Article en En | MEDLINE | ID: mdl-37671649
With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly, inform treatment decision-making, its value in the context of lower-intensity regimens is unclear. As such regimens have gained in popularity and can be associated with higher response rates, the need to better define the role of MRD assessment and the appropriate time points and assays used for this purpose has increased. This report outlines a roadmap for MRD testing in patients with AML treated with lower-intensity regimens. Experts from the European LeukemiaNet (ELN)-DAVID AML MRD working group reviewed all available data to propose a framework for MRD testing in future trials and clinical practice. A Delphi poll served to optimize consensus. Establishment of uniform standards for MRD assessments in lower-intensity regimens used in treating patients with AML is clinically relevant and important for optimizing testing and, ultimately, improving treatment outcomes of these patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos